Quick Answer
Opus Genetics, Inc. reported Stockholders Equity of $15.35 million for fiscal year 2025.
Opus Genetics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $15.35M | +128.3% |
| 2024 | $6.72M | -86.5% |
| 2023 | $49.91M | +7.9% |
| 2022 | $46.24M | +108.1% |
| 2021 | $22.22M | +265.0% |
| 2020 | -$13.47M | -78.1% |
| 2019 | -$7.56M | -345.0% |
| 2018 | -$1.70M | -110.1% |
| 2017 | $16.77M | -1.7% |
| 2016 | $17.06M | -9.1% |
| 2015 | $18.78M | -29.4% |
| 2014 | $26.58M | +110.5% |
| 2013 | $12.63M | +32.4% |
| 2012 | $9.53M | -10.9% |
| 2011 | $10.71M | +3.0% |
| 2010 | $10.40M | +112.0% |
| 2009 | $4.90M | +288.4% |
| 2008 | -$2.60M | -371.6% |
| 2007 | $958.2K | -70.2% |
| 2006 | $3.21M | -33.5% |
| 2005 | $4.83M | +956.0% |
| 2004 | -$564.2K | -122.8% |
| 2003 | $2.48M | -8.7% |
| 2002 | $2.71M | -30.3% |
| 2001 | $3.89M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.97M | -82.6% | -65.9% |
| June 30, 2025 | $17.47M | -57.0% | +244.4% |
| March 31, 2025 | $5.07M | -89.0% | -24.6% |
| December 31, 2024 | $6.72M | -86.5% | -80.4% |
| September 30, 2024 | $34.30M | -31.8% | -15.6% |
| June 30, 2024 | $40.64M | +7.8% | -11.8% |
| March 31, 2024 | $46.06M | +11.7% | -7.7% |
| December 31, 2023 | $49.91M | +7.9% | -0.7% |
- Opus Genetics, Inc. showed an increase of +128.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2001–2025 period, Opus Genetics, Inc.’s stockholders equity has grown by 294.1% (from $3.89 million to $15.35 million).
- The most recent figure is from Opus Genetics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: